EXPRESS INC (EXPR)

US30219E2028 - Common Stock

2.29  +0.06 (+2.69%)

Fundamental Rating

2

EXPR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 126 industry peers in the Specialty Retail industry. While EXPR is still in line with the averages on profitability rating, there are concerns on its financial health. EXPR does not seem to be growing, but still is valued expensively.



4

1. Profitability

1.1 Basic Checks

EXPR had negative earnings in the past year.
EXPR had a negative operating cash flow in the past year.
In multiple years EXPR reported negative net income over the last 5 years.
In multiple years EXPR reported negative operating cash flow during the last 5 years.

1.2 Ratios

EXPR has a better Return On Assets (12.19%) than 88.28% of its industry peers.
With an excellent Return On Equity value of 120.91%, EXPR belongs to the best of the industry, outperforming 97.66% of the companies in the same industry.
Industry RankSector Rank
ROA 12.19%
ROE 120.91%
ROIC N/A
ROA(3y)-2.64%
ROA(5y)-3.25%
ROE(3y)-1730.52%
ROE(5y)-1046.08%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 10.01%, EXPR belongs to the top of the industry, outperforming 92.97% of the companies in the same industry.
EXPR's Profit Margin has improved in the last couple of years.
EXPR's Gross Margin of 22.40% is on the low side compared to the rest of the industry. EXPR is outperformed by 76.56% of its industry peers.
EXPR's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 10.01%
GM 22.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y78.26%
GM growth 3Y1.31%
GM growth 5Y-0.5%

1

2. Health

2.1 Basic Checks

EXPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EXPR has more shares outstanding
Compared to 5 years ago, EXPR has less shares outstanding
The debt/assets ratio for EXPR has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.97, we must say that EXPR is in the distress zone and has some risk of bankruptcy.
EXPR has a worse Altman-Z score (0.97) than 69.53% of its industry peers.
EXPR has a Debt/Equity ratio of 1.83. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.83, EXPR is not doing good in the industry: 67.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.83
Debt/FCF N/A
Altman-Z 0.97
ROIC/WACCN/A
WACC15.82%

2.3 Liquidity

A Current Ratio of 0.98 indicates that EXPR may have some problems paying its short term obligations.
EXPR has a worse Current ratio (0.98) than 86.72% of its industry peers.
A Quick Ratio of 0.19 indicates that EXPR may have some problems paying its short term obligations.
With a Quick ratio value of 0.19, EXPR is not doing good in the industry: 85.94% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.19

3

3. Growth

3.1 Past

EXPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -521.75%.
EXPR shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 76.94% yearly.
Looking at the last year, EXPR shows a decrease in Revenue. The Revenue has decreased by -8.11% in the last year.
Measured over the past years, EXPR shows a decrease in Revenue. The Revenue has been decreasing by -2.89% on average per year.
EPS 1Y (TTM)-521.75%
EPS 3YN/A
EPS 5Y76.94%
EPS growth Q2Q29.1%
Revenue 1Y (TTM)-8.11%
Revenue growth 3Y-2.63%
Revenue growth 5Y-2.89%
Revenue growth Q2Q4.6%

3.2 Future

EXPR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.01% yearly.
EXPR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.32% yearly.
EPS Next Y-135.77%
EPS Next 2Y14.55%
EPS Next 3Y16.01%
EPS Next 5YN/A
Revenue Next Year-1.98%
Revenue Next 2Y2.16%
Revenue Next 3Y2.32%
Revenue Next 5YN/A

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

EXPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EXPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

EXPR's earnings are expected to grow with 16.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.55%
EPS Next 3Y16.01%

0

5. Dividend

5.1 Amount

EXPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

EXPRESS INC

NYSE:EXPR (3/6/2024, 7:04:00 PM)

2.29

+0.06 (+2.69%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.59M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.19%
ROE 120.91%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) 10.01%
GM 22.4%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 1.83
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.98
Quick Ratio 0.19
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-521.75%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-135.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-8.11%
Revenue growth 3Y-2.63%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y